Clinical Trials Logo

Raynaud Disease clinical trials

View clinical trials related to Raynaud Disease.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04915950 Terminated - Clinical trials for Raynaud's Phenomenon Secondary to Systemic Sclerosis

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Start date: November 3, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether oral temanogrel improves digital blood flow in participants with Raynaud's phenomenon secondary to systemic sclerosis (SSc-RP) as a potential safe and effective treatment for symptoms associated with SSc-RP.

NCT ID: NCT03869008 Terminated - Raynaud Phenomenon Clinical Trials

Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.

Start date: April 30, 2019
Phase: N/A
Study type: Interventional

Raynaud's phenomenon (RP) is a common vascular disorder that affects approximately 10% of the general population. RP is associated with significant morbidity that may include loss of the digits due to repeated episodes of vasospasm of the digital arteries in addition to significant impairment of quality of life. It is well known that cold exposure precipitates episodes of RP, but the mechanism for cold sensitivity is not known, and treatment of RP is not satisfactory to the patients and their physicians. The goal in this study is to test the possibility that non invasive vagus nerve stimulation (nVNS) with gammaCore which is already approved by the FDA for headaches and migraines may be an effective and well tolerated therapy for Raynaud's Phenomenon.

NCT ID: NCT03639766 Terminated - Raynaud Phenomenon Clinical Trials

The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon

Start date: August 31, 2018
Phase: Phase 4
Study type: Interventional

This study aims to investigate the effect of abobotulinum toxin A on the symptoms of Raynaud's phenomenon.

NCT ID: NCT02642146 Terminated - Systemic Sclerosis Clinical Trials

Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study

Start date: January 2015
Phase:
Study type: Observational [Patient Registry]

This study evaluates the efficacy and safety of routine medical treatments of digital ulcers in patients with systemic sclerosis in a prospective cohort study.

NCT ID: NCT02374320 Terminated - Clinical trials for Peripheral Vascular Disease

Exparel as a Nerve Block for Severe Hand Pain

Start date: November 2014
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to investigate whether the use of the study drug (Exparel) is safe and effective for treating circulation problems and pain in the hand or fingers.

NCT ID: NCT01315899 Terminated - Clinical trials for Raynaud's Phenomenon

Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon

REINO
Start date: March 2011
Phase: Phase 2
Study type: Interventional

Raynaud's phenomenon (RP) is a disorder of the digital blood vessels resulting in episodic impairment of blood flow. During an attack of RP which commonly affects the hands and feet these arteries contract briefly which limits the blood flow (this is called a vasospasm) and deprived of blood the skin turns white then blue. The aim of this study is to prove the concept that ORM-12741 can prevent these blood vessel spasms.